SGMT — SAGIMET BIOSCIENCES INC. SERIES A COMMON STOCK (Healthcare >> Biotechnology)
SGMT FAQ
What is SGMT's ROE?
SAGIMET BIOSCIENCES INC. SERIES A COMMON STOCK reports a Return on Equity (ROE) of -42.47%.
What is SGMT's dividend yield?
SAGIMET BIOSCIENCES INC. SERIES A COMMON STOCK offers a dividend yield of 0.00%.
What is SGMT's Deepscope Quality Score?
Deepscope rates SGMT's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SGMT?
Deepscope's AI Timing Score for SGMT is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SGMT belong to?
SAGIMET BIOSCIENCES INC. SERIES A COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 6.48
Price
0.05
(0.78%)
Day Change
|
|
|---|
SGMT, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 6.48 |
| PBV / Sector |
3.88 / 4.91
|
| Earning Per Share | -0.71 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
5.04 M
GREAT
|
| Average 1W Daily Value |
4.18 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-13 11:12:59 |
| Symbol | SGMT |
| Name | SAGIMET BIOSCIENCES INC. SERIES A COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 61.18 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 397.06 / 9,034.83 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 155 Bovet Road, San Mateo, CA, United States, 94402
Phone: 650 561 8600
Website: https://www.sagimet.com
Sector: Healthcare >> Biotechnology
Description: Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google